Alexander RB et al. (2004) Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. Ann Intern Med 141: 581–589
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)—characterized by pain or discomfort in the pelvic region lasting more than 3 months—is difficult to treat because its cause is unknown. Antibiotic therapy with agents such as ciprofloxacin is widely used, even though there is frequently no infection of the prostate. Alternatively, α-blockers such as tamsulosin are often prescribed. A new study by Alexander et al. has compared these treatments with placebo in men with long-standing symptoms of CP/CPPS.
A total of 196 patients, all of whom had received prior treatment for CP/CPPS, were randomly assigned to ciprofloxacin (500 mg twice daily), tamsulosin (0.4 mg once daily), both drugs, or placebo, with 49 patients in each group. After 6 weeks' treatment, all treatment groups showed a slight decrease in NIH-CPSI scores compared to baseline, but neither drug showed a significant difference compared with placebo. Secondary outcomes, including changes in the quality-of-life, pain and voiding subscales of the NIH-CPSI, were also similar in all treatment groups.
Alexander et al. conclude that ciprofloxacin and tamsulosin, both common treatments for CP/CPPS, were not effective in this study. It is possible that including patients who were naïve to treatment and/or extending the duration of therapy might result in improved symptom scores. The authors note, however, that the design of the study reflected current practice.
Rights and permissions
About this article
Cite this article
Prostatitis and pelvic pain: assessment of current treatments. Nat Rev Urol 2, 4 (2005). https://doi.org/10.1038/ncpuro0061
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0061